Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Results
..
All razuprotafib studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchRazuprotafibRazuprotafib (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   All Outcomes       

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

Paggiarino et al., NCT04511650, RESCUE, NCT04511650
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -5% Improvement Relative Risk Death or respiratory failure -178% Discharge -469% Razuprotafib  RESCUE  LATE TREATMENT  DB RCT Is late treatment with razuprotafib beneficial for COVID-19? Double-blind RCT 31 patients in the USA Higher progression (p=0.37) and lower discharge (p=0.28), not sig. c19early.org Paggiarino et al., NCT04511650, February 2021 Favorsrazuprotafib Favorscontrol 0 0.5 1 1.5 2+
RCT 29 patients showing no significant differences with razuprotafib treatment.
Standard of Care (SOC): SOC for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
risk of death, 5.3% higher, RR 1.05, p = 1.00, treatment 2 of 19 (10.5%), control 1 of 10 (10.0%).
death or respiratory failure, 177.8% higher, RR 2.78, p = 0.37, treatment 5 of 18 (27.8%), control 1 of 10 (10.0%), day 28.
risk of no hospital discharge, 468.7% higher, RR 5.69, p = 0.28, treatment 3 of 16 (18.8%), control 0 of 9 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Paggiarino et al., 26 Feb 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04511650 (history) (RESCUE). Contact: dpaggiarino@eyepointpharma.com.
This PaperRazuprotafibAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0